Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Uremic platelet dysfunction: past and present.

Gines Escolar1, Maribel Díaz-Ricart, Aleix Cases

  • 1Servicio de Hemoterapia y Hemostasia and Servicio de Nefrología, Hospital Clínic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain. gescolar@clinic.ub.es

Current Hematology Reports
|September 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.

Frontiers in immunology·2026
Same author

Frailty and Congestion in Patients with Heart Failure: Clinical Interaction and Prognostic Implications.

Journal of clinical medicine·2026
Same author

Impaired hemostasis in mechanical circulatory support systems: Monitoring with T-TAS® 01, in vitro correction with VWF concentrates, and impact of membrane oxygenators.

Heart & lung : the journal of critical care·2026
Same author

Platelet dynamics in methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia: Distinct patterns and prognostic implications.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Common Biomarkers of Endothelial Dysfunction Across Highly Prevalent Diseases with Cardiovascular Risk: Functional Characterization and Prognostic Implications.

International journal of molecular sciences·2026
Same author

Diagnostic performance of flow cytometric osmotic fragility testing in hereditary spherocytosis.

Cytometry. Part B, Clinical cytometry·2026
Same journal

Safety and efficacy of argatroban in patients with heparin-induced thrombocytopenia.

Current hematology reports·2006
Same journal

The treatment of immune thrombocytopenic purpura in children.

Current hematology reports·2006
Same journal

Volume-reduced platelet concentrates.

Current hematology reports·2006
Same journal

Platelet transfusions in infants with necrotizing enterocolitis.

Current hematology reports·2006
Same journal

Methods for counting platelets in severe thrombocytopenia.

Current hematology reports·2006
Same journal

Flow cytometry for the diagnosis of autoimmune thrombocytopenia.

Current hematology reports·2006
See all related articles

Patients with kidney failure experience impaired platelet function, leading to bleeding issues. Improved treatments for uremic platelet dysfunction are revealing a paradoxical increase in clotting risks.

Area of Science:

  • Nephrology
  • Hematology
  • Pathophysiology

Background:

  • Uremic patients exhibit acquired platelet dysfunction, increasing bleeding risks.
  • Pathogenesis involves toxins, vascular changes, anemia, and hemodialysis effects.
  • Understanding uremic hemostatic dysfunction has evolved significantly.

Purpose of the Study:

  • To review the evolution of knowledge on uremic platelet dysfunction.
  • To examine how research has improved understanding and therapeutic strategies.
  • To highlight the paradoxical coexistence of bleeding and thrombosis risks.

Main Methods:

  • Literature review focusing on uremic platelet dysfunction.
  • Analysis of hemostatic alterations in kidney disease.
  • Synthesis of research on therapeutic interventions.

Related Experiment Videos

Main Results:

  • Advances in understanding uremic platelet dysfunction mechanisms.
  • Development of effective therapeutic strategies for bleeding.
  • Emergence of increased thrombotic complications as bleeding is controlled.

Conclusions:

  • Uremic platelet dysfunction is multifactorial with complex hemostatic alterations.
  • Therapeutic progress has improved bleeding control but revealed new risks.
  • A delicate balance exists between deficient hemostasis and thrombosis risk in uremia.